ArticleLeukemia2025
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.
Abstract read
In one paragraph
Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognostic implications ofBlood neoplasia · 2026Article
- One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol.Blood cancer journal · 2026Article
- Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study.British journal of haematology · 2026Article
- Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia.Current hematologic malignancy reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Clifford M CsizmarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0002-1221-8854
Anuya NatuDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Mark GurneyDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0002-7062-2644
Saubia FathimaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0002-9979-7923
Ali Khalid A AlsugairDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Rashmi Kanagal-ShamannaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-7829-5249
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-8980-3202
Alexandre BazinetDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Kelly ChienDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-6024-1613
Danielle HammondDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-6017-2264
Courtney DiNardoDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-9003-0390
Tapan KadiaDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-9892-9832
Farhad Ravandi-KashaniDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-7621-377X
Naveen PemmarajuDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-1670-6513
Koji SasakiDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-9140-0610
Terra L LashoDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Christy M FinkeDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Aref Al-KaliDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Hassan AlkhateebDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0002-3609-8404
Kebede BegnaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0003-2730-8593
Naseema GangatDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Mehrdad Hefazi TorghabehDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0001-8860-3380
Aasiya MatinDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Abhishek A MangaonkarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0003-2458-9887
Antoine N SalibaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0001-5134-7336
Ayalew TefferiDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0003-4605-3821
Guillermo Garcia-ManeroDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-3631-2482
Hagop M KantarjianDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Rami S KomrokjiDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, 33612, USA.ORCID http://orcid.org/0000-0002-1876-5269
Zhuoer XieDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, 33612, USA.ORCID http://orcid.org/0000-0003-1266-9804
Najla A AliDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, 33612, USA.
David SallmanDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, 33612, USA.ORCID http://orcid.org/0000-0003-0504-8233
Eric Padron *Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, 33612, USA.ORCID http://orcid.org/0000-0002-4707-7916
Guillermo Montalban-Bravo *Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-4533-5176
Mrinal M Patnaik *Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA. patnaik.mrinal@mayo.edu.ORCID http://orcid.org/0000-0001-6998-662X
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
PMID
40555734What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.